第6笔成交价格为11.31元，成交100.00万股，成交金额1,131.00万元，溢价率为-8.86%，买方营业部为机 构专用，卖方营业部为东吴证券股份有限公司苏州狮山路证券营业部。 第3笔成交价格为11.31元，成交20.00万股，成交金额226.20万元，溢价率为-8.86%，买方营业部为机构 专用，卖方营业部为东吴证券股份有限公司苏州狮山路证券营业部。 第4笔成交价格为11.31元，成交153.00万股，成交金额1,730.43万元，溢价率为-8.86%，买方营业部为机 构专用，卖方营业部为东吴证券股份有限公司苏州狮山路证券营业部。 第5笔成交价格为11.31元，成交100.00万股，成交金额1,131.00万元，溢价率为-8.86%，买方营业部为机 构专用，卖方营业部为东吴证券股份有限公司苏州狮山路证券营业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月10日，阿特斯收跌4.69%，收盘价为12.41元，发生7笔大宗交易，合计成交量500万股，成交金额 5655万元。 第1笔成交价格为11.31元，成交36.00万股，成交金额407.16万元，溢价率为-8.86%， ...

华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 2025 年半年度跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：东星医疗 | | --- | --- | | 保荐代表人姓名：庄晨 | 联系电话：025-83388070 | | 保荐代表人姓名：黄飞 | 联系电话：025-83388070 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | - | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | - | | （1）是否督导公司建立健全规章制度（包括但不限于防止关 联方占用公司资源的制度、募集资金管理制度、内控制度、 | 是 | | 内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | - | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理 ...

Market Overview - The Shanghai Composite Index closed at 3813.56 points, with a decline of 1.16% [1] - The total trading volume of A-shares reached 23956.82 billion yuan [1] Technical Analysis - A total of 16 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sichuang Medical (300078) with a distance of -0.91% - Nanmo Biology (688265) with a distance of -0.80% - Shandong Weida (002026) with a distance of -0.75% [1] Individual Stock Performance - Sichuang Medical (300078) saw a decrease of 2.81% with a trading turnover rate of 3.15% [1] - Nanmo Biology (688265) decreased by 0.16% with a turnover rate of 1.39% [1] - Shandong Weida (002026) declined by 2.93% with a turnover rate of 2.90% [1] - Qingda Environmental (688501) dropped by 3.86% with a turnover rate of 1.84% [1] - Pulit (002324) fell by 2.62% with a turnover rate of 2.03% [1] - Other notable declines include: - Meili (000815) down by 4.03% - Hezhong (002383) down by 6.95% [1]

Financial Performance - The company's total revenue for the first half of 2025 was 183 million yuan, a decrease of 14.17% year-on-year [1] - The net profit attributable to shareholders was 30.29 million yuan, down 36.47% year-on-year [1] - In Q2 2025, total revenue was 105 million yuan, a decline of 13.66% year-on-year, with net profit of 18.23 million yuan, down 34.4% [1] - The gross profit margin was 46.77%, a decrease of 2.1% year-on-year, while the net profit margin was 16.18%, down 27.2% [1] - Total operating expenses (selling, administrative, and financial) amounted to 54.64 million yuan, accounting for 29.81% of revenue, an increase of 16.68% year-on-year [1] Balance Sheet and Cash Flow - The company's cash and cash equivalents decreased by 68.30% to 63.49 million yuan [1] - Accounts receivable stood at 83.57 million yuan, a decrease of 9.38% year-on-year, but accounted for 85.78% of net profit [1][3] - Interest-bearing liabilities increased significantly by 528.41% to 89.40 million yuan [1] Return on Investment - The company's return on invested capital (ROIC) was 4.17%, indicating weak capital returns [3] - The historical median ROIC since the company went public is 7.89%, suggesting average investment returns [3] - The net profit margin for the previous year was 22.25%, indicating high added value in products or services [3]

Group 1 - The core viewpoint of the article highlights Dongxing Medical's focus on the development and production of minimally invasive surgical instruments, with a recent emphasis on the all-electric endoscopic stapler [1] - Dongxing Medical reported a revenue of 183 million yuan and a net profit attributable to shareholders of 30.29 million yuan for the first half of the year [1] - The company has completed the registration of the all-electric endoscopic stapler as a Class III medical device and has launched it in the market [1] Group 2 - Dongxing Medical is also in the process of registering the ultrasonic scalpel head and main unit for Class III medical device certification [1] - On August 27, the stock price closed at 27.90 yuan, down 0.57% from the previous trading day, with a trading volume of 1.61 billion yuan [1] - On the same day, there was a net inflow of 729,900 yuan in main funds, although the overall trend over the past five days showed a net outflow of 10.2 million yuan [1]

Core Viewpoint - Dongxing Medical (301290) reported a decline in revenue and net profit for the first half of 2025, with a focus on upgrading its product lines and expanding its market presence in response to changing market conditions [2][3][4]. Financial Performance - In the first half of 2025, Dongxing Medical achieved revenue of 183 million yuan, a year-on-year decrease of 14.17%, and a net profit attributable to shareholders of 30 million yuan, down 36.47% [2]. - The sales revenue from the anastomosis device segment was 97 million yuan, reflecting a year-on-year growth of 7%, while revenue from anastomosis device components fell to 32.16 million yuan, a decline of 44.45% [2]. Business Strategy - The company has terminated funding for the capacity construction project of the anastomosis device components segment as part of its strategic adjustments [2]. - Dongxing Medical is focusing on the intelligent and electric upgrades of its laparoscopic anastomosis products and aims to develop a multi-category surgical equipment and medical consumables platform [2][3]. Product Development - The company has successfully obtained Class III medical device registration for its manual, electric, and fully electric laparoscopic anastomosis devices, which are now on the market [2]. - Dongxing Medical is developing a new generation of fully electric laparoscopic cutting anastomosis devices, which are expected to have significantly higher gross margins compared to traditional electric products [2]. R&D Focus - The company is also prioritizing the development of disposable electric anal ligators, which were launched in 2024, addressing complexities in traditional ligation techniques [3]. - Dongxing Medical is working on multiple new models of anal ligators to enhance its product line and market influence [3]. - The company is pursuing the registration of ultrasonic knife heads and main units as Class III medical devices, targeting the minimally invasive surgery market [3]. Market Trends - The minimally invasive surgical field is experiencing a clear trend towards intelligence and domestic production, with the laparoscopic anastomosis device market expected to grow at a compound annual growth rate of 6.15% from 2022 to 2030 [3]. - The domestic market for electric laparoscopic anastomosis devices had a localization rate of 22% in 2022, indicating a significant acceleration in the domestic substitution process [3]. Future Outlook - In 2024, revenue from electric anastomosis devices grew by over 130% year-on-year, becoming a key driver of the company's performance [4]. - The medical device subsidiary, Weike Medical, added 12 new medical device registration certificates and 22 new patent technologies in the first half of 2025, enhancing the company's product and technology reserves for future growth [4].

Core Viewpoint - Dongxing Medical announced that it will hold its second extraordinary general meeting of shareholders on September 15, 2025, to review multiple proposals, including the formulation and revision of certain corporate governance systems [1] Group 1 - The extraordinary general meeting is scheduled for September 15, 2025 [1] - The meeting will discuss various proposals, including governance system revisions [1]

江苏东星智慧医疗科技股份有限公司 董事会薪酬与考核委员会工作细则 第一条 为进一步建立健全江苏东星智慧医疗科技股份有限公司（以下称公 司）董事及高级管理人员的薪酬与考核管理制度，完善公司治理结构，根据《中 华人民共和国公司法》《上市公司治理准则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件和《公司章 程》的规定，公司设立董事会薪酬与考核委员会，并制定本细则。 第二章 人员组成 2025 年 8 月 江苏东星智慧医疗科技股份有限公司 董事会薪酬与考核委员会工作细则 第三条 薪酬与考核委员会由三名董事组成，其中独立董事应当过半数。 第四条 薪酬与考核委员会由董事长、二分之一以上独立董事或者全体董事 的三分之一薪酬与考核，并由董事会选举产生。 第一章 总则 第二条 薪酬与考核委员会是董事会下设的专门工作机构，主要负责研究公 司董事及高级管理人员的考核标准，进行考核并提出建议；负责研究、制定、审 查公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第五条 薪酬与考核委员会设召集人一名，由独立董事成员担任。召集人由 董事会任命，负责召集和主持薪酬与考核委员会工 ...

江苏东星智慧医疗科技股份有限公司 董事和高级管理人员所持本公司股份 及其变动管理制度 1 江苏东星智慧医疗科技股份有限公司 董事和高管人员所持本公司股份及其变动管理制度 第一章 总则 第一条 为规范江苏东星智慧医疗科技股份有限公司（以下称公司）董事、 高级管理人员买卖公司股票及持股变动行为，进一步明确办理程序，根据《中华 人民共和国公司法》（以下称《公司法》）、《中华人民共和国和证券法》（以 下称《证券法》）、《上市公司董事和高级管理人员所持本公司股份及其变动管 理规则》《深圳证券交易所上市公司自律监管指引第 10 号-股份变动管理》等法 律、法规、规范性文件以及《江苏东星智慧医疗科技股份有限公司章程》（以下 称《公司章程》）等规定，结合公司的实际情况，特制定本制度。 第二条 本制度适用于公司董事、高级管理人员，其所持本公司股票是指登 记在其名下的所有本公司股份；从事融资交易融券交易的，还包括记载在其信用 账户内的本公司股份。 第三条 本公司董事、高级管理人员在买卖公司股票及其衍生品种前，应知 悉《公司法》、《证券法》等法律、法规、部门规章及规范性文件关于内幕交易、 操纵市场、短线交易等禁止行为的规定，不得进 ...

江苏东星智慧医疗科技股份有限公司 董事会审计委员会工作细则 2025 年 8 月 江苏东星智慧医疗科技股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化江苏东星智慧医疗科技股份有限公司（以下称公司）董事会 决策功能，健全董事会的审计评价和监督机制，确保董事会对高级管理层的有效 监督，进一步完善公司治理结构，根据《中华人民共和国公司法》（以下称《公 司法》）、《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等法律法规、规范性文件和《公司章程》的规定， 公司设立董事会审计委员会，并制定本细则。 第二条 审计委员会是董事会下设的专门工作机构，行使《公司法》规定的 监事会的职权，并负责审核公司财务信息及其披露、监督及评估内外部审计工作 和内部控制。 第二章 人员组成 第三条 审计委员会由三名以上不在公司担任高级管理人员的董事组成，其 中独立董事应当过半数。公司董事会成员中的职工代表可以成为审计委员会成员。 审计委员会成员应当勤勉尽责，切实有效地监督、评估上市公司内外部审计 工作，促进公司建立有效的内部控制并提供真实、准确、完整的财务报告。 审计委员会成 ...